Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03718273
Other study ID # BRAKE-AF
Secondary ID 2018-001936-23
Status Completed
Phase Phase 3
First received
Last updated
Start date October 19, 2018
Est. completion date June 30, 2022

Study information

Verified date October 2022
Source Hospital Universitario 12 de Octubre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The BRAKE-AF Study is a phase III, randomised, controlled, multicentric, open-label clinical trial to prove the noninferiority of ivabradine versus digoxin in the treatment of permanent atrial fibrillation. The total duration of the study is 3 years, with 24 months of enrolment, treatment and follow-up.


Description:

This is a non-commercial, investigator-driven clinical study funded through a public competitive call by Instituto de Salud Carlos III, Spanish Ministry of Economy (PI17/01272). The study is coordinated by the main investigator from Hospital Universitario 12 de Octubre in Madrid; the sponsorship is performed by Dr. Adolfo Fontenla (Hospital Universitario 12 de Octubre). Several responsibilities are delegated to the Clinical Research Unit (Hospital 12 de Octubre, Madrid, Spain). The study was planned according to the Good Clinical Practices. BRAKE-AF Study has been approved by the Ethics Committee and Spanish Health Authorities. All participating patients must give written informed consent before any study procedure occur.


Recruitment information / eligibility

Status Completed
Enrollment 68
Est. completion date June 30, 2022
Est. primary completion date February 22, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years. 2. Permanent Atrial Fibrillation (AF) at the time of randomization, with no prospect of cardioversion, antiarrhythmic treatment with group I or III drugs, or pulmonary vein ablation. 3. Symptoms attributable to AF associated with the presence of at least one of the following inadequate Heart rate (HR) control criteria: 1. HR at rest > 110 bpm (on ECG -electrocardiogram- performed in the 14 days prior to inclusion). 2. HR at rest between 80 and 110 bpm (on ECG performed in the 14 days prior to inclusion) and at least one of the following criteria: i. HR in exercise of moderate intensity > 130 bpm (measured in an ergometry or in a Holter-ECG performed in the 60 days prior to inclusion). ii. Average daytime HR > 80 bpm (measured on a Holter-ECG performed in the 60 days prior to inclusion). 4. Be receiving treatment with beta-blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem) at the maximum dose recommended or tolerated by the patient. 5. Be able to voluntarily give their informed consent. 6. B|ood test carried out in the 6 months prior to inclusion' including: blood count, thyroid hormones and creatinine, in order to rule out secondary causes of poor HR control. The creatinine figure will be used to calculate the creatinine clearance in order to adjust the dose of patients who are randomized to the Digoxin group. 7. Transthoracic echocardiogram to rule out, eg, severe valvular heart disease, hypertrophic cardiomyopathy. The one performed in the year prior to inclusion in the study will be considered acceptable provided that the patient's clinical situation has been stable in that period of time. Exclusion Criteria: 1. Previous treatment or patients with a known contraindication to Ivabradine or Digoxin or to any excipient of both drugs. 2. Paroxysmal or intermittent complete atrioventricular (AV) block in patients not carrying a pacemaker. 3. Decompensated heart failure requiring inotropic and I or intravenous diuretics in the week prior to randomization or in New York Heart Association (NYHA) functional class IV or on the cardiac transplant waiting list, 4. Acute pericarditis, acute myocarditis or constrictive pericarditis. 5. Obstructive hypertrophic cardiomyopathy. 6. Valvular disease requiring surgical or percutaneous correction. 7. Medical causes that justify poor control of heart rate: fever' anemia, hyperthyroidism, pheochromocytoma' etc. 8. Severe hypotension (blood pressure <90/50 mmHg). 9. Concomitant treatment with potent cytochrome P450 3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, oral erythromycin, josamycin, telithromycin) HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone. 10. Severe renal insufficiency (CrCl <30 ml/Kg/min) or in a hemodialysis program. 11. Severe hepatic insufficiency. 12. Major surgery (including cardiac surgery) in the month prior to randomization. 13. Severe concomitant illness that supposes a llfe expectancy of less than one year. 14. Impossibility of carrying out scheduled visits to the protocol. 15. Woman of childbearing age (under 50 years of age, except for those who present a gynecological report that proves the presence of menopause) and women who are breastfeeding. 16. Participation in a clinical trial in the previous 6 months. 17. Patients with acute myocardial infarction or unstable angina. 18. Patient with a recent stroke. 19. Patients with congenital long QT syndrome or treated with drugs that prolong this interval.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ivabradine
Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month. Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good
Digoxin
The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance <60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.

Locations

Country Name City State
Spain Hospital Universitario de Burgos Burgos
Spain Fundación Jiménez Díaz Madrid
Spain Hospital Clínico San Carlos Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario de Getafe Madrid
Spain Hospital Universitario La Paz Madrid
Spain Hospital Universitario Puerta de Hierro Madrid
Spain Hospital Universitario Ramón y Cajal Madrid
Spain Hospital Universitario Rey Juan Carlos Madrid
Spain Hospital Virgen de la Salud Toledo

Sponsors (3)

Lead Sponsor Collaborator
Adolfo Fontenla Carlos III Health Institute, Spanish Clinical Research Networt (SCReN)

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Heart rate reduction. Reduction of the mean daytime heart rate registered in Holter- electrocardiogram (ECG) after treatment with Ivabradine or Digoxin. 3 months
Primary Serious adverse events Proportion of patients experiencing syncope, severe bradycardia or any serious adverse reaction requiring hospitalization, emergency visit or death of the patient during treatment with Ivabradine or Digoxin. 3 months
Secondary Reduction in the scale of atrial fibrillation (AF) symptoms according to the European Hearth Rhythm Association (EHRA) Score modified. Percentage of patients who experience a reduction in the scale of atrial fibrillation. symptoms according to the EHRA Score modified. Months 1 and 3.
Secondary 6 minute walk test (6MWT). Increase in meters in the 6MWT. Baseline and after 3 months.
Secondary Quality-of-Life Short Form 36 (SF-36) Health Survey (QoL SF-36) Score. Increase in the score obtained in global quality of life parameters analyzed by the SF-36 questionnaire. At baseline and 3 months.
Secondary The Atrial Fibrillation Effect on Quality-of-Life (QoL AFEQT) score. Increase in the score obtained in parameters of quality of life quality of life associated with AF analyzed by the AFEQT questionnaire. At baseline and 3 months
Secondary Reduction of the daytime Health rate. Reduction of the average daytime Heart Rate (HR) recorded in Holter-ECG 1 month
Secondary Reduction of resting Health Rate. Reduction of resting heart rate (HR) recorded on one electrocardiogram (ECG). 1 and 3 months
Secondary Reduction of the maximum heart rate (HR) recorded. Reduction of the maximum HR recorded in Holter-ECG 1 and 3 months
Secondary Reduction of the mean HR recorded. Reduction of the mean HR in 24 hours recorded in Holter-ECG . 1 and 3 months
Secondary Reduction of the HR delta. Reduction of the HR delta (difference between maximum HR and mean HR in 24 hours) recorded in Holter-ECG. 1 and 3 months
Secondary Reduction of HR in moderate exercise. Reduction of HR in moderate exercise (maximum HR measured by Holter-ECG during the 6-minute walk test. 3 months
Secondary Percentage of patients with non-severe bradycardia. Percentage of patients who experience non-severe bradycardia during the study treatment. 1 and 3 months
Secondary Percentage of patients who experience any adverse reaction. Percentage of patients who experience any adverse reaction to the study drugs. 1 and 3 months
Secondary Percentage of patients who voluntarily abandon the study drugs. Percentage of patients who voluntarily abandon the study drugs. 3 months
Secondary Proportion of hospitalizations, emergency visits and mortality due to a major cardiovascular event. Proportion of patients experiencing hospitalizations, emergency visits and mortality due to a major cardiovascular event during treatment with the study drug. 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A